Vaxcyte, Inc.

Vaxcyte, Inc.

PCVXNYSE / NASDAQHealthcareSmall cap

$55.39-$2.97 (-5.1%)

Last close · Data as of Nov 20, 2026

Market cap
$7.0B
P/E
-9.2x
EV / EBITDA
-7.8x
Revenue
$0.00
ROCE
-33.0%

+16.2% over the last year

Vaxcyte, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.4%
3M
-9.7%
6M
+17.4%
1Y
+16.2%
5Y
+143.9%

52-week range

Day change -$2.97 (-5.1%) from $58 to $55 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PCVX, bought on each weekday since 2021.

News & filings

What Vaxcyte filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 767 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.91 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Read moreShow less

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Sector
Healthcare
Shares outstanding
131.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.0B
P/E
-9.2x
P/B
2.6x
EV / EBITDA
-7.8x
52-week high
$73.82
52-week low
$43.06

Profitability

ROE
-28.5%
ROCE
-33.0%
ROIC
-27.8%
ROA
-25.5%

Growth

Revenue
$0.00
Net profit growth, 1Y
65.2%
Free cash flow
-$712.5M

Solvency

Current ratio
7.91
Debt / Equity
0.04
Debt / Assets
0.04
CFO / Net profit
0.86
Cash / Market cap
2.5%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Vaxcyte, Inc. revenue and net profit by fiscal year
Vaxcyte, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$223.5M
FY2023$0.00-$402.3M
FY2024$0.00-$463.9M
FY2025$0.00-$766.6M

Cash flows

FY2025: -$655.6M from operations, -$712.5M free after investment (dashed).

Vaxcyte, Inc. operating and free cash flow by fiscal year
Vaxcyte, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$170.6M-$176.4M
FY2023-$296.8M-$364.7M
FY2024-$452.6M-$571.8M
FY2025-$655.6M-$712.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$898.8M
Net profit
-$766.6M
Cash from operations
-$655.6M
Free cash flow
-$712.5M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$898.8M-$766.6M-$712.5M-28.5%—+65.2%

Monthly returns

Month-by-month returns of PCVX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.0B
Liabilities$317.2M
Equity$2.7B
Paid-in capital$4.8B
Retained earnings-$2.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PCVX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Vaxcyte, Inc., Praxis Precision Medicines, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Vaxcyte, Inc.PCVXthis company$7.0B-9.2x2.6x-28.5%-7.8x
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Immunovant, Inc.IMVT$6.7B-13.3x7.9x-59.3%-10.9x
Lantheus Holdings, Inc.LNTH$6.7B28.7x6.1x21.4%17.2x
Peer median—-16.1x7.7x-31.4%-16.2x

Year-to-date ROI

PCVX since 1 January, against earlier years.

Historical volatility

PCVX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$923.7M
Research and developmentResearch And Development$794.3M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$923.7M
Pretax incomePretax Income-$766.6M

Learn while you research

Academy chapters picked for Vaxcyte, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →